HTAi_AM22_program_digital_website

WORKSHOPS WS13 An Introduction To Early Health Technology WS15 Introduction to Ethics in Health Technology Assessment Assessment 08:30 - 12:00, Room 215 13:00 - 16:30, Room 110 Speakers: Janneke Grutters, Netherlands Speakers: Duncan Steele, Canada Marcia Tummers, Netherlands Dario Sacchini, Italy Geert Frederix, Netherlands Gert Jan van der Wilt, Netherlands Kari Kværner, Norway Bart Bloemen, Netherlands Linn Støme, Norway Lars Sandman, Sweden Ken Bond, Canada WS09 HTA 102. Hospital-Based HTA 08:30 - 12:00 & 13:00 - 16:00, Room 114 WS16 Reducing the Computational Burden of Health Economic Models and Analyses Using Metamodeling Speakers: Marco Marchetti, Italy 13:00 - 16:30, Room 215 Laura Sampietro-Colom, Spain Rossella Di Bidino, Italy Speakers: Koen Degeling, Netherlands Kristian Kidholm, Denmark Hendrik Koffijberg, Netherlands Americo Cicchetti, Italy WS14 Exploring Methods for Evaluating Impact of WS17 The Use of Evidence-Informed Deliberative Patient and Public Involvement in the Assessment of Processes for Health Technology Assessment in Low Technologies Along their Lifecycle and Middle Income Countries 13:00 - 16:30, Room 117 13:00 - 16:30, Room 315 Speakers: Wija Oortwijn, Netherlands Rob Baltussen, Netherlands Speakers: Anke-Peggy Holtorf, Switzerland Leon Bijlmakers, Netherlands Ann Single, Australia Richmond Owusu, Ghana Ana Toledo Chávarri, Spain Maryam Huda, Pakistan Lidewij Eva Vat, Netherlands Lyazzat Kosherbayeva, Kazakhstan Sophie Staniszewska, United Kingdom Veronica Lopez Gousset, France Aline Silveira Silva, Canada

PANELS Panels 63

PANELS Panels Monday, June 27, 2022 PN04 Horizon Scanning for New and Emerging Technologies. Experiences Along the World, so PN01 Building Bridges Between Patient and Similar, so Different Treatment - Perspectives On Harmonizing Health Technology Assessment with Up and Down-Stream 14:20 - 15:35, Room 315 Stakeholders 14:20 - 15:35, Room 114 Panelists Iñaki Gutierrez-Ibarluzea Hans-Peter Dauben Panelists Milou Hogervorst, Netherlands Izzuna-Mudla Mohamed Ghazali Mathias Møllebæk, Denmark Dawn Craig François Houÿez, France Dana Horáková, Czech Republic PN05 Developing HTA in the Balkans - A Road map Nick Crabb, United Kingdom for Success with International Collaboration Xavier Kurz, Netherlands 14:20 - 15:35, Room Virtual PN02 Health Technology Assessment in Situations of Panelists Sarah Garner, Netherlands Uncertainty: The Case of COVID-19 Aljosa Djudurovi, Bosnia and Herzegovina 14:20 - 15:35, Room 117 Spela Zerovnik, Slovenia Panelists Diana Delnoij, Netherlands Dalia Dawoud, United Kingdom Jamie Elvidge, United Kingdom PN06 A Lifecycle Approach to Promote Engagement Harald Miedema, Netherlands and Efficiency in HTA: 2022 HTAi Global Policy Juan Carlos Réjon-Parrilla, Spain Forum Summary PN03 The Year of Change: From National to 14:20 - 15:35, Room Beatrix Theatre European Health Technology Assessment Procedures Panelists Dan Ollendorf, United States Rebecca Trowman, Australia 14:20 - 15:35, Room 417 Herve Nabarette, France Rick Vreman, Netherlands Panelists Zoe Garrett, United Kingdom Susan Myles, United Kingdom Alric Rüther, Germany Linetta Koppert, Netherlands

PANELS PN07 Working Together in Health Technology PN11 Can Social Media Research Help to Improve Assessment on Oncology Immunotherapy Lifecycle: Public Confidence in Health Technology Assessment Opportunities and Challenges in East Asia (HTA) and Healthcare Decision Making? 14:20 - 15:35, Room Virtual 17:15 - 18:30, Room 215 Panelists Yingyao Chen, China Panelists Anke-Peggy Holtorf, Switzerland Jeonghoon Ahn, South Korea Joey Mattingly, United States Ruoyan Gai, Japan Li-Ying (Grace) Huang, Taiwan Lizheng Shi, United States Alissa Hanna, United States Aline Silveira Silva, Canada PN08 Expedited Pathways for Drug Approval: PN12 Would the Novel Elements of Value Contribute Aligning Regulators, HTA Agencies, Payers, Patients, to Equitable Access to New Medical Technologies? - Clinicians and Industry A Multistakeholder Perspective 14:20 - 15:35, Room 215 Panelists Sean Tunis, United States 17:15 - 18:30, Room 315 Nikas Hedberg, Sweden Bettina Ryll, Sweden Panelists Wim Goettsch, Netherlands Chris Henshall, United Kingdom Ramiro Gilardino, United States Andrew Bruce, Australia Valentina Strammiello, Belgium PN09 The International Horizon Scanning Initiative: PN13 Deep Dive on Uncertainty - A Multistakeholder Empowering Governments to Identify and Negotiate Discussion Hosted by the HTAi-DIA Joint Working Fair Prices for Innovative Health Technologies Group 17:15 - 18:30, Room 417 17:15 - 18:30, Room 114 Panelists Inka Heikkinen, Denmark Wija Oortwijn, Netherlands Panelists Diana Delnoij, Netherlands Milou Hogervorst, Netherlands Marcus Guardian, Netherlands Iñaki Gutierrez-Ibarluzea, Spain Niels Speksnijder, Netherlands Neil Bertelsen, Germany Sari Susanna Ormstad, Norway Dimitra Lingri, Greece PN10 From Thought to Action: Legitimate Decision Making and the Role of Stakeholders in the HTA Processes 17:15 - 18:30, Room Virtual Panelists Zinaida Bezverhni, Moldova Gavin Surgey, Netherlands Augustina Koduah, Ghana Rob Baltussen, Netherlands

PANELS PN14 Deliberative Processes for Informed Decision Tuesday, June 28, 2022 - Making by Health Technology Assessment: HTAi Latin America Policy Forum 2021 Findings PN17 Fit for Purpose Novel Payment Models to Increase Patient Access to Cell and Gene Therapies: 17:15 - 18:30, Room Beatrix Theatre Let’s Work Together Panelists Manuel Espinoza, Chile 11:35 - 12:50, Room Virtual Andres Pichon-Riviere, Argentina Vania Canuto, Brazil Panelists Renske ten Ham, Netherlands Alicia Granados, Spain Simon Walker, United Kingdom Jurgen Kuball, Netherlands PN15 Patient and Public Participation in Health Olivia Wu, United Kingdom Technology Assessment’s Organization Domain: Declan Noone, Belgium Approaches and Opportunities PN18 Real-World Evidence’s Role in Lifecycle 17:15 - 18:30, Room 117 Management: Learnings from ICER and NICE’s Demonstration Projects Panelists Ann Single, Australia 11:35 - 12:50, Room 117 Hervé Nabarette, France Isabelle Ganache, Canada Panelists Ashley Jaksa, United States Irina Cleemput, Belgium Jon Campbell, United States Seamus Kent, United States PN16 Impact of Health Policies on HTA Riad Dirani, United States 17:15 - 18:30, Room Virtual PN19 Journal Submissions - Some Useful Tips for Success Panelists Karen Facey, United States Nicole Mitmann, Canada Herve Nabarette, France 11:35 - 12:50, Room 215 Sheela Upadhyaya, United Kingdom Jo-anne Watson, Australia Panelists Wendy Babidge, Australia Wim Goettsch, Netherlands Jani Mueller, South Africa Joseph Mathew, India PN20 Developing a Multi-Stakeholder Shared Learning Platform to Improve Understanding in the Use and Acceptance of RWE 11:35 - 12:50, Room 315 Panelists Deven Chauhan, United Kingdom Felix Greaves, United Kingdom Bettina Ryll, Sweden Shahid Hanif, Canada

PANELS PN21 Joint Scientific Consultations: How Will the PN25 Enhancing ‘Public Confidence in Healthcare Present Inform the Future? Decision-Making’ in Low-and Middle-Income Countries Through Stakeholder- and Context- 11:35 - 12:50, Room 417 Conscious Health Technology Assessment (HTA) Panelists Anne Willemsen, Netherlands 16:55 - 18:10, Room 114 Antje Behring, Germany Anja Schiel, Norway Panelists Jani B. Muller, South Africa Claudine Sapede, Switzerland Anke-Peggy Holtorf, Switzerland Susanne Teupen, Germany Lauren Pretorius, South Africa Narendra Javadekar, India PN22 The Added Value of a Value-Oriented Izzuna Mudla Mohamed Ghazali, Perspective in Health Technology Assessment Malaysia 11:35 - 12:50, Room 114 PN26 How may the Lifecycle Approach feed into HTA Capacity Building Strategies in Low- and Panelists Bart Bloemen, Netherlands Middle-Income Countries (LMICs)? Carla Fernandez Barceló, Spain Faye Freriks, Netherlands 16:55 - 18:10, Room Virtual Joan Escarrabill, Spain Panelists Sharif Qaddomi, Palestine Richmond Owusu, Ghana PN23 A Lifecycle Approach in Assessing Digital Katrine Frønsdal, Norway Applications: In Silos or Teaming Up Internationally? Sarah Garner, Netherlands Lieke Heupink, Norway 11:35 - 12:50, Room Beatrix Theatre Panelists Laura Sampietro-colom, Spain PN27 Sustainable Modeling: Taking a Lifecycle Marcia Tummers, Netherlands Approach to Model Development to Increase Kristian Kidholm, Denmark Assessment Efficiency and Validity Jeanette Kusel, United States Cristina Bescos, Spain 16:55 - 18:10, Room 215 PN24 Applying Patient Preferences in HTA: Do Panelists Hendrik Koffijberg, Netherlands Preferences and Can Preferences Influence HTA Marjan Hummel, Netherlands Decision Making? \\ Mohamed El Alili, Netherlands Koen Degeling, Australia 11:35 - 12:50, Room Virtual Saskia Knies, Netherlands Panelists Deborah Marshall, Canada Simon Fifer, Australia Barry Stein, Canada Barry Liden, United States

PANELS PN28 EU HTA Regulation: Improved Access or PN32 Do Differences in HTA Deliberative Structures Layering of Processes? Affect Confidence in the Outputs? A Discussion and Proposed Research Agenda 16:55 - 18:10, Room 315 16:55 - 18:10, Room 117 Panelists Dima Samaha, United Kingdom Anne Willemsen, Netherlands Sara Lopes, Brazil Panelists Daniel Ollendorf, United States Mihai Rotaru, Belgium Ken Bond, Canada Sheela Upadhyaya, United Kingdom PN29 Patient Registries Providing Real-World Jacqueline Zwaap, Netherlands Evidence to Support a Lifecycle Approach for HTA of Evelyn Thsehla, South Africa Expensive Drugs, from Different Perspectives (COI) 16:55 - 18:10, Room 417 Wednesday, June 29, 2022 Panelists Dorien Lobbezoo, Netherlands PN33 Patient Involvement in Health Technology Wim Goettsch, Netherlands Assessment (HTA) – Are We All on the Same Page? Mariëtte Driessens, Netherlands Daphne Schoenmakers, Netherlands 09:25 - 10:40, Room 315 PN30 HTA in Asia Post-COVID-19: HTAi Asia Policy Panelists Anke-Peggy Holtrof, Switzerland Forum 2021 Findings Niel Bertelsen, Germany Maria Dutarte, Netherlands 16:55 - 18:10, Room Beatrix Theatre Lonneke Timmers, Netherlands Hannes Jarke, Belgium Panelists TBD PN34 Creating Political, Societal and Professional Support for Sustainable Healthcare Choices PN31 Regulatory and Health Technology 09:25 - 10:40, Room Beatrix Theatre Assessment Alignment: A Match Made in Heaven or Irreconcilable Differences? Panelists Diana Delnoij, Netherlands Gijsbert Werner, Netherlands 16:55 - 18:10, Room Virtual Sarah Kleijnen, Netherlands Meindert Boysen, United Kingdom Panelists Jacoline Bouvy, United Kingdom Patrick Jeurissen, Netherlands Anja Schiel, Norway Huseyin Naci, United Kingdom Bettina Ryll, Sweden Sjaak Wijma, Netherlands

PANELS PN35 Qualitative Evidence: A Methodology That Can PN38 Outcome-Based Reimbursement and Guide Lifecycle Health Technology Assessment Delayed-payment Schemes for New Technologies Central and Eastern European and Middle Eastern 09:25 - 10:40, Room 417 Countries Panelists Alessandra Lo Scalzo, Italy 09:25 - 10:40, Room 215 Karen Macpherson, United Kingdom Sophie Söderholm Werkö, Sweden Panelists Marcelien Callenbach, Netherlands Iñaki Gutierrez-Ibarluzea, Spain Ildiko Ádám, Hungary Deirdre DeJean, Canada Rabia Kahveci, Turkey Iga Lipska, Poland Wim Goettsch, Netherlands PN36 Beyond Checking the Boxes: Guidance Of PN39 A Lifecycle Approach to HTA: The Role of The Joint HTAi – ISPOR Task Force Deliberative Implementation Alongside Economic Evaluation Processes for HTA 09:25 - 10:40, Room 114 09:25 - 10:40, Room Virtual Panelists Wija Oortwijn, Netherlands Panelists Robert Heggie, United Kingdom Don Husereau, Canada Ties Hoomans, United Kingdom Jacqueline Zwaap, Netherlands Simon Walker, United Kingdom Li-Ying (Grace) Huang, Taiwan Caroline Clarke, United Kingdom Vania Canuto, Brazil Edward Clifton, United Kingdom PN37 Collaboration to Overcome Challenges in PN40 Value From a Multi-stakeholder Perspective: Generation and Interpretation of Evidence for Rare An Assessment Framework for Digital Health Disease Treatments Solutions to Improve Chronic Disease Management 09:25 - 10:40, Room 117 09:25 - 10:40, Room Virtual Panelists Karen Facey, United Kingdom Panelists Panos Kanavos, United Kingdom Eric Low, United Kingdom Madeleine Haig, United Kingdom Alfonso Iorio, Canada Charlie Nicholls, United Kingdom Anja Schiel, Norway Jean Mossman, United Kingdom Sheela Upadhyaya, United Kingdom Federico Augustovski, Argentina Alicia Granados, Spain

Radboud university medical centre Free download (CC BY-NC-ND 4.0) at — Department for Health Evidence www.radbouduniversitypress.nl and www.validatehta.eu Radboud university medical centre (Radboudumc), located ISBN 9789083178950 in Nijmegen, is one of the eight university hospitals in the DOI https://doi.org/10.54195/CKHB1659 Netherlands. It specializes in patient care, scientific research, teaching and training in order to have a significant impact on In the 2018-2021 EU Erasmus+ strategic partnerships project healthcare. “VALues In Doing Assessments of healthcare TEchnologies” (VALIDATE), a consortium of seven academic and HTA organ- The HTA group, part of the Department for Health Evidence, izations have developed an approach to HTA that allows for is internationally recognized for its excellent reputation in the integration of empirical analysis and normative inquiry. research and education in health sciences. The group has broad in-house knowledge and expertise about all aspects The VALIDATE handbook offers the reader an opportunity to related to HTA. get acquainted with the theoretical considerations and ap- prehend the associated practical and organizational implica- The activities are centered around the development of HTA tions of this approach. It offers those interested in HTA to reports, methodologies to improve decision-making pro- integrate empirical analysis and normative inquiry in a trans- cesses as well as improving the institutional HTA capacity in parent way. countries around the globe. Examples include the VALIDATE approach (see The VALIDATE handbook) and Evidence-Informed The handbook is endorsed by HTAi and EuroScan-iHTS. Deliberative Processes (EDP) for HTA. The EDP guide can be downloaded via: https://www.radboudumc.nl/en/research/ research-groups/global-health-priorities/our-products/prac- tical-guide/practical-guide. The research program of the HTA group serves as basis for academic teaching, training of Master and PhD students and those interested in HTA and global health.

ORALS Orals 71

ORALS Oral Presentations Monday, June 27, 2022 OP06 Percutaneous Transforaminal Endoscopic Discectomy: From Insufficient Evidence to OS01 Discrete Choice Experiments Reimbursement (DCE) Speaker: Hedi Schelleman, Netherlands Monday, June 27, 2022 - 12:10 - 13:10, Room 114 OS03 Economic Evaluations OP01 Convergent Validity Between Discrete Choice Experiment and Other Stated Preference Methods: A Monday, June 27, 2022 - 12:10 - 13:10, Room 215 Multi Study Comparison OP08 Early Access to New Direct-acting Antiviral: A Speaker: Jorien Veldwijk, Netherlands Journey on Introduction of Ravidasvir for Hepatitis C Treatment in Malaysia OP02 The Use of Discrete Choice Experiments for Measuring Patient Preferences in Health Technology Speaker: Nazatul Syima Idrus, Malaysia Assessment OP09 Cost-Effectiveness of Laparoscopic Speaker: Michael Strauss, South Africa Supracervical Hysterectomy Versus 2nd-Generation Endometrial Ablation for Treatment of Heavy OP03 Patient Characteristics Affect Their Treatment Menstrual Bleeding (The Health Trial) Choice: A Discrete Choice Experiment With Breast Cancer Patients in Six European Countries Speaker: Rodolfo Hernández, United Kingdom Speaker: Eugena Stamuli, United Kingdom OP10 Outcomes of Expanded Access to Transcatheter Aortic Valve Implantation in Ontario: A OS02 Early HTA Model-Based Analysis Monday, June 27, 2022 - 12:10 - 13:10, Room 117 Speaker: Rafael Miranda, Canada OP04 Methodological Challenges of Assessing an OS04 European Collaboration Evolving Technology: The Cochlear Implant for Deaf People Monday, June 27, 2022 - 12:10 - 13:10, Room 315 Speaker: Hugo Nijmeijer, Netherlands OP11 Differences and Similarities in Past Health Technology Assessments in Beneluxa Initiative OP05 The Role of Conditional Reimbursement in the Countries Lifecycle Approach Speaker: Rick Vreman, Netherlands Speaker: Hedi Schelleman, Netherlands

ORALS OP12 Post-Launch Evidence Generation Among OP18 Clinical Effectiveness and Safety of Health Technology Assessment Bodies in Europe Implantable Bulking Agents for Faecal Incontinence: A Systematic Review Speaker: Leonor Varela Lema, Spain Speaker: Lucia Gassner, Austria OP13 EUnetHTA Relative Effectiveness Assessments of Pharmaceutical and Other Technologies: OP19 Comparative Effectiveness of Common Procedural Changes Implemented During Joint Treatment Options for Benign Prostatic Hyperplasia: Action 3 A Systematic Review and Network Meta-Analysis Speaker: Sabine Ettinger, Austria Speaker: Sirikan Rojanasarot, United Kingdom OS05 Patient and Clinician OS07 Quality of Evidence Involvement Monday, June 27, 2022 - 12:10 - 13:10, Virtual Monday, June 27, 2022 - 12:10 - 13:10, Beatrix Theatre OP20 Is the Quality of Evidence in HTA Deteriorating Over Time?: A Case Study on Cancer Drugs in Australia OP14 Involving People With a Lived Experience When Developing a Proposed Health Technology Speaker: Yuan Gao, Australia Assessment of Pelvic Organ Prolapse Treatments OP21 A Critical Review of Existing Health Inequality Speaker: Eugenie Johnson, United Kingdom and Health Inequity Frameworks in Evidence Synthesis OP15 Improving the Osteoporosis Care Trajectory by Collaboration Between Clinicians, Patients and Speaker: Patience Kunonga, United Kingdom Health Insurers Within the Appropriate Care Program OP22 Using Threshold Analysis to Guide Searches Speaker: Iris Groeneveld, Netherlands for Additional Sources of Evidence OP16 Learning From Engagement With Human Speaker: Sumayya Anwer, United Kingdom Immunodeficiency Virus Community Organisations In The Health Technology Assessment Lifecycle OS09 HTA in World Speaker: Heidi Livingstone, United Kingdom Monday, June 27, 2022 - 15:45 - 16:45, Room 114 OS06 Systematic Reviews for HTA OP26 Policy Perspectives of Health Technology Assessment in Ethiopia Monday, June 27, 2022 - 12:10 - 13:10, Room 417 Speaker: Desalegn Ararso, Ethiopia OP17 Robotic Versus Conventional Surgery: An Overview of Systematic Reviews for Clinical Effectiveness with OP27 Health Technology Assessment Processes, Quality Assessment of Current Evidence Characteristics, and Key differences in High, Middle, and Low-income Countries of Asia Pacific Region Speaker: Tzujung Lai, United Kingdom Speaker: Ashish Verma, India

ORALS OP28 Health Technology Assessment: A situation OS12 Life Cycle Analysis Of Zimbabwe Monday, June 27, 2022 - 15:45 - 16:45, Room 315 Speaker: Blessing Dzingirai, Zimbabwe OP35 Suitability of Preference Methods Across the OS10 Artificial Intelligence Medical Product Lifecycle: A Multi Criteria Decision Analysis Monday, June 27, 2022 - 15:45 - 16:45, Room 117 Speaker: Jorien Veldwijk, Netherlands O86 Chatbot-Based Symptom-Checkers: A Systematic Review OP36 A Lifecycle Approach in Evaluating Medical Technologies: Insights from NICE’s Guidance Review Speaker: Reinhard Jeindl, Austria Process OP30 Model for Assessing the Value of AI in Medical Speaker: Ivan Maslyankov, United Kingdom Imaging (MAS-AI) OP37 Lifecycle Evaluation Models and Frameworks Speaker: Iben Fasterholdt, Denmark Used to Assess Medical Devices: A Qualitative Evidence Synthesis OP31 Assessment of AI Supported Health Technologies - How to Move Forward? Speaker: Kathleen Harkin, Ireland Speaker: Signe Daugbjerg, Italy OS13 Pricing OS11 Horizon Scanning - Monday, June 27, 2022 - 15:45 - 16:45, Room 417 Collaboration OP38 Managed (Early) Access in England: The ‘Ins Monday, June 27, 2022 - 15:45 - 16:45, And Outs’ Beatrix Theatre Speaker: Charlotte Bee, United Kingdom OP32 A Multi-Step Multi-Stakeholder Priority Setting Exercise for Faecal Incontinence OP39 The Real-Option Rate of Return Approach to Inform the Pricing of Medicines Speaker: Nicole O’connor, United Kingdom Speaker: Simon van der Schans, The Netherlands OP33 Expectations, Needs and Challenges of Setting Up an International Collaboration for Horizon OP107 The Assessment Of The Price Of A Medicine: Scanning of Medical Devices The Possible Application Of Cost-Based Pricing Methods Speaker: Renee Else Michels, Netherlands Speaker: Sibren Van Den Berg, The Netherlands OP34 Horizon Scanning a Matter of Collaboration. A Description of the Processes of i-HTS Member Organisations Speaker: Iñaki Gutierrez-ibarluzea, Spain

ORALS OS 14 Real World Data - Use OS16 Multi Stakeholder Involvement Monday, June 27, 2022 - 15:45 - 16:45, Virtual Monday, June 27, 2022 - 15:45 - 16:45, Room 215 OP41 Facilitating Dialogue of RWE Use in HTA: OP47 Parallel Procedure Regulatory and Health Taxonomy of Question/Data Source Pairings to Technology Assessment: Accelerating Access for Support a Registry of Studies Patients Speaker: Ronald Akehurst, United Kingdom Speaker: Simone De Vries, Netherlands OP42 Increasing Access to Real World Data to Move OP48 Interactions Between Regulatory, HTA From Health Technology Assessment to Health and Companies: A Multi-Stakeholder Survey on Technology Management the Current Experiences and Future Landscape Evolvement Speaker: Shaun Rowark, United Kingdom Speaker: Tina Wang, United Kingdom OP43 Conceptual and Methodological Factors Driving the Integration of Real-world Evidence in OP49 A Systematic Review of the Activities of Early Drugs and Technologies Reimbursement Appraisals Advice, Early Dialogue, Scientific Advice by HTA Doers Speaker: Geneviève Plamondon, Canada Speaker: Nora Ibargoyen-Roteta, Spain OS15 Diabetes/Obesity Tuesday, June 28, 2022 Monday, June 27, 2022 - 15:45 - 16:45, Virtual OS17 Children and Pediatrics OP44 Does the Health Economic Modelling Structure Matter? An External Validation of Three Tuesday, June 28, 2022 - 09:50 - 11:05, Room 114 Approaches Commonly Used in Obesity Modelling OP50 Health Equity Considerations in HTA: A Case Speaker: Bjoern Schwander, Germany Example of Prenatal Screening OP45 Screening Prediabetes Using 1 hour Glucose. Speaker: Beth Shaw, United States A Simulation Model to Estimate the Lifetime Health and Economic Outcomes OP51 Improving Childhood Cancer Management and Financing in Ghana: Results From Stakeholder Speaker: Martina Andellini, Italy Mapping and Analysis OP46 Assessing the Quality of Pharmacoeconomic Speaker: Richmond Owusu, Ghana Evaluations about Type 2 Diabetes Mellitus Drugs in National Reimbursement Drug List OP52 Health Technology Assessment of Pain-Free Blood Draw Devices in Pediatrics Speaker: Yingyao Chen, China Speaker: Ilaria Cristiano, Italy

ORALS OP53 Downstream Cost Savings of Genome-Wide OP60 Methodological Guidance and Doctrine of the Sequencing for Childhood Developmental Disorders French National Authority for Health for Economic and Early-Onset Seizures: A Bench to Bedside Evaluation Analysis Speaker: Véronique Raimond, France Speaker: Deirdre Weymann, Canada OP61 Developing a Core Dataset for the Economic OS18 Horizon Scanning Evaluation of Precision Oncology: A Multi-Stage Approach to Enhanced Data Infrastructure Tuesday, June 28, 2022 - 09:50 - 11:05, Room 117 Speaker: Samantha Pollard, Canada OP54 The Early Detection and Warning System “SINTESIS-new technologies”: A Horizon Scanning OS20 Patient Perspectives Experience in Spain Tuesday, June 28, 2022 - 09:50 - 11:05, Speaker: Ana Isabel Hijas-Gómez, Spain Beatrix Theatre OP55 Classification System for Innovative Medicines OP62 Patients’ Ppinion on Health Technology in the Pipeline: New or Repurposed? Assessment (HTA) Reports: An Analysis of Brazilian HTA in 2021 Speaker: Ross Fairbairn, United Kingdom Speaker: Denis Satoshi Komoda, Brazil OP56 A Life Cycle Approach to Horizon Scanning Outputs - From Signals to Guidelines OP63 Patient and Public Perspectives on the Scottish Medicines Consortium Detailed Advice Document Speaker: Sarah Khan, United Kingdom Speaker: Miranda Pierre, United Kingdom OP57 The Identification of Technological Innovations to Address the Challenge of OP64 NICE Listens: Engaging the Public on How to Antimicrobial Resistance Using Horizon Scanning Address Health Inequalities in Health Technology Approaches Assessment and Guideline Development Speaker: Lucy Barrass, United Kingdom Speaker: Katherine Cresswell, United Kingdom OS19 Guidance for HTA OP65 An Overview of Participatory Approaches Used in the Development of Medical Devices: A Scoping Tuesday, June 28, 2022 - 09:50 - 11:05, Room 215 Review OP59 The Tunisian Guidelines for Pharmacoeconomic Speaker: Kasper Woudstra, Netherlands Analysis: What We Need to Know Speaker: Nabil Harzallah, Tunisia

ORALS OS21 Treatment Value Speaker: Kevin Kallmes, United States Tuesday, June 28, 2022 - 09:50 - 11:05, Room 417 OP73 Tools That Can Aid Adaptive HTA to Ensure Rapid, Efficient, rend Pragmatic Priority Setting: A OP66 Low-Value Pharmaceutical Care Among Scoping Review Dutch General Practitioners: A Retrospective Cohort Speaker: Lieke Fleur Heupink, Norway Speaker: Joris Muskens, Netherlands OS23 COVID OP67 Considerations of Treatment Novelty in Health Tuesday, June 28, 2022 - 09:50 - 11:05, Virtual Technology Assessment OP74 Assessing Public Confidence Towards Speaker: Patricia Synnott, United States COVID-19 Vaccines Through Social Media Insights Leveraged Using Artificial Intelligence Techniques OP68 Real-World Experience with NICE’s Willingness Speaker: Kate Lanyi, United Kingdom to Accept Less Costly, Less Effective Healthcare Technologies OP76 “Thunderbirds Are Go!” Rapid Response HTA Outputs for COVID-19 Speaker: Edel Falla, United Kingdom Speaker: Lirije Hyseni, United Kingdom OP69 Seeking A Better End - Development of a OP77 Covidiagnostix: Health Technology Healthcare Technology Data System Assessing Assessment for Vaccination Strategy Definition Quality of In-Hospital End-of-Life Care Speaker: Selenia Marino, Italy Speaker: Elisa Neves, Brazil OS24 Environmental Impact OS22 HTA Tools Tuesday, June 28, 2022 - 09:50 - 11:05, Room 315 Tuesday, June 28, 2022 - 09:50 - 11:05, Virtual OP78 Taking a Societal Perspective in Health Technology Assessment: Is Environmental Impact a OP70 Gaps in the Evaluation of Clinical Decision Special Case? Support Software (CDSS): Interviews with Australian Speaker: Juliet Kenny, United Kingdom Policymakers OP79 Incorporating Environmental Impacts into Speaker: Mah Laka, Australia Health Technology Assessment: An Examination of Potential Approaches and Challenges OP71 PriTec Tool 2: Adaptation for Selection of Speaker: Juliet Kenny, United Kingdom Technologies to be Assessed for Inclusion into the Health Care System Speaker: Leonor Varela Lema, Spain OP72 Software Tools for Systematic Literature Review in Medicine: A Review and Feature Analysis

ORALS OP80 ‘Green Metrics’ - Incorporating Environmental OP07 Dealing with Uncertainty In Early Health Dimensions in Health Technology Assessment Technology Assessment: An Exploration of Methods For Decision Making Under Deep Uncertainty Speaker: Tjerk Jan Schuitmaker-Warnaar, Netherlands Speaker: Mirre Scholte, Netherlands OP81 Do Sustainable Healthcare Principles Inform OS27 Virtual Guidance Development?: An Exemplary Case Study in Respiratory Care Tuesday, June 28, 2022 - 14:00 - 15:00, Room 215 Speaker: Sarah Walpole, United Kingdom OP88 Drawing Lines in The Sand: How do we Define the Scope of Analysis in HTA and Economic OS25 Patient Involvement Evaluation? Tuesday, June 28, 2022 - 14:00 - 15:00, Speaker: Marina Richardson, Canada Beatrix Theatre OP89 The CE-Signal, a New Simplified HTA Method OP82 Patient Involvement in Health Technology to Determine Whether Interventions are Cost- Assessment in Implementation Health Technology Effective Assessment Speaker: Joost Enzing, Netherlands Speaker: Lyazzat Kosherbayeva, Kazakhstan OP90 Optimizing Health Technology Assessment OP83 Joining Efforts to Improve Patient Involvement and Appraisal for Orphan Drug Reimbursement: in Health Technology Assessment: The Case of the Experiences and Tools for Improvement RedETS Patient Interest Group Speaker: Alessandra Blonda, Belgium Speaker: Yolanda Trinanes, Spain OS28 Real World Data - Impact OP84 Cost Consequence Analysis: A Potential Framework to Incorporate Patient Preferences Into Tuesday, June 28, 2022 - 14:00 - 15:00, Room 315 Health Technology Assessment and Reimbursement Decisions OP91 The Current State of Disease-Specific Registries for the Monitoring of Expensive Speaker: Jennifer Whitty, United Kingdom Pharmaceuticals in the Netherlands OS26 Decision Making Speaker: Wim Goettsch, Netherlands Tuesday, June 28, 2022 - 14:00 - 15:00, Room 117 OP92 Impact of Real-World Evidence on Health Technology Assessment and National Guidance for OP23 Managing Uncertainty in Precision Oncology Interventional Procedures: A UK Perspective Decision-Making: Stakeholder Perspectives and Recommendations for Improved Processes Speaker: Lakshmi Mandava, United Kingdom Speaker: Samantha Pollard, Canada

ORALS OP93 Informing Efficient Diagnostic Monitoring OP99 A Comparison of Three Methods for Multi- Pathways Using Prospective Cohort Data: A stakeholder Engagement: Focus Groups, Interviews, Case Study in Neovascular Age-Related Macular and Surveys Degeneration Speaker: Kasper Woudstra, Netherlands Speaker: Graham Scotland, United Kingdom OS32 Priority Setting OS29 PROMS Tuesday, June 28, 2022 - 14:00 - 15:00, Virtual Tuesday, June 28, 2022 - 14:00 - 15:00, Room 417 OP103 Enhancing Legitimacy and Coherent Value OP94 OPUF: A New Online Tool for Eliciting EQ-5D- Appraisal Across Interventions in Health Care and 5L Value Sets on the Societal-, Group-, Subgroup-, Social Services: The INESSS Strategy and Individual Person-Level Speaker: Mireille Goetghebeur, Canada Speaker: Paul Schnieder, Germany OP105 Gaps, Challenges and Priorities for OP95 Examining the Feasibility and Acceptability of Neurodegenerative Disease Research and Health Valuing the Lebanese Version of the SF-6D using Technology Assessment Standard Gamble Speaker: Dalia Dawoud, United Kingdom Speaker: Samer Kharroubi, Lebanon OP100 Research ‘As’ Policy: Overview of Four OP96 Patient Reported Outcome Measure-Select Years Interactive Research of the Dutch Healthcare App Institute on Medical Innovations Speaker: Elise Quik, The Netherlands Speaker: Payam Abrishami, Netherlands OS30 Stakeholder Engagement Tuesday, June 28, 2022 - 14:00 - 15:00, Room 114 OP97 Stakeholders’ Involvement in Brazilian Health Technology Assessment Incorporation (HTAi) in 2021: A Statistical Description of Demands to CONITEC Speaker: Denis Satoshi Komoda, Brazil OP87 Value From A Multi-stakeholder Perspective: A Framework To Assess Digital Health Solutions For Improving Chronic Disease Management Speaker: Madeleine Haig, United Kingdom

Roche HTAi Symposium Monday, 27 June 2022 | 13.15 - 14.15 CEST Making Gene and Cell Therapies a Reality for Patients How HTA and Novel Payment Solutions Play a Central Role 80

POSTERS Posters 81

POSTERS Poster Presentations Poster Presentations Session 1: PP90 Startup and Inclusion Problems in Healthcare Monday June 27, 10:25 – 10:35 Efficiency Studies, a Quantitative and Qualitative Analysis COVID & Patient/Public/Children Presenter: Karen van Liere-Visser, Netherlands Poster Stand 4, Mies Bouwman Foyer HTA Findings PP10 Impact of Covid-19 on the Management of Poster Stand 5, Mies Bouwman Foyer Breast Cancer in Italy: The Perspectives of Patients and Coordinators PP59 Multidimensional Evaluation of the Reducer Device in Patients with Refractory Angina Presenter: Eugenio Di Brino, Italy Presenter: Filippo Rumi, Italy PP11 Impact of Qualitative Research in the Spanish PP60 Cost -Effectiveness Analysis of the SPRINTT Network of HTA Multicomponent Protocol Presenter: Filippo Rumi, Italy Presenter: Ana Toledo-Chávarri, Spain PP61 Plugging the Gap of Fetoscopy in Congenital PP12 Challenges in Assessing the Efficacy of Non- Diaphragmatic Hernia Pregnancies: Value for Pharmacological Measures in the Context of the Money? Covid-19 Pandemic Presenter: Jip Janssen, Netherlands Presenter: Lorena Aguilera-Cobos, Spain Lifecycle (Cost) Effectiveness Early & General Lifecycle Poster Stand 2, Mies Bouwman Foyer Poster Stand 1, Mies Bouwman Foyer PP04 We Can Help People Who Feel Lonely - A Systematic Review on Loneliness Interventions PP01 Early HTA at work to ensure focus mechanisms Presenter: Claus Loevschall, Denmark to foster patient access and understanding of medicinal product information(ePI) Presenter: Eva Turk, Norway PP89 Stimulating and Assuring Evidence Quality from a Dutch Funders’ Perspective – Introducing the ZonMw Reporting Checklist Presenter: Wendy Rijmerink, Netherlands

POSTERS PP05 Effect Modifiers in Indirect Treatment Poster Presentations Session 2: Comparisons: Guidance Is Needed to Ensure an Monday June 27, 13:25 – 13:35 Unbiased Identification in Decision Making COVID & Patient/Public/Children Presenter: Andreas Freitag, United Kingdom Poster Stand 4, Mies Bouwman Foyer PP06 Clinical Effectiveness of Fluticasone Furoate Nasal Spray for Perennial Allergic Rhinitis in Children: PP25 Brazilian Collaborative Network for Covid-19 A Systematic Re-View and Meta-Analysis Modelling: Successful Experience of Using Real- Time Science to Support Evidence-Based Decision Presenter: Paola Rivera, Peru Making Lifecycle RWD & Quality of Care & Presenter: Michelle Rosa, Brazil Disinvestment PP26 Cost-Utility of Vaccination Against Covid-19 In Poster Stand 3, Mies Bouwman Foyer Brazil PP07 Improving the Use of Real-World Evidence in Presenter: Carlos Magliano, Brazil the Development of NICE Guidance PP27 Reusing and Adapting Health Technology Presenter: Seamus Kent, United Kingdom Assessments (HTAs): An Example From the COVID-19 Time PP08 Evaluation of Nutritional Status in Diabetic and Non-Diabetic Chronic Kidney Disease Patients Using Presenter: Maria-Jose Faraldo-Valles, Spain a Web Tool Early & General Lifecycle Presenter: Ishfaq Rashid, India Poster Stand 1, Mies Bouwman Foyer PP09 Use of Real-World Evidence for Managing Health Technologies Throughout the Life Cycle of PP16 Machine Learning in the Treatment of Spinal Transcatheter Aortic Valve Interventions Deformities: Early Life-cycle Economic Analysis in Australia Presenter: Catherine Truchon, Canada Presenter: Rashmi Joglekar, Australia PP17 Can Pritec Tool to be Useful in the Identification of Disruptive Healthcare Technologies? Presenter: Janet Puñal-Riobóo, Spain PP18 Horizon Scanning for Clinical Biosimilar Medicines: Informing the Lifecycle of Health Technology Assessment and Market Access Presenter: Amy Hussain, United Kingdom

POSTERS HTA Findings Lifecycle RWD & Quality of Care & Disinvestment Poster Stand 5, Mies Bouwman Foyer Poster Stand 3, Mies Bouwman Foyer PP153 The Economic and Fiscal Impact of Public Health Programs for Diabetic Patients in Italy PP22 A Lifecycle Approach to the Use of RWE in HTA Submissions and Re-Submissions, a Decade’s Presenter: Eugenio Di Brino, Italy Experience PP154 Associations of Orphan Designation and Presenter: Dima Samaha, United Kingdom other Drug Development-Related Factors on the Rollout times and Health-Technology-Assessment PP23 Lost in Translation? The Differences in the Use Recommendations of New-Active-Substances of Real-World Evidence Across Key Markets Presenter: Belen Sola, United Kingdom Presenter: Weiwei XU, Netherlands PP155 Impact of Parallel Submission On The PP24 Organizing Outpatient Parenteral Antibiotic Rollout Time and Health-Technology-Assessment Therapy: Lessons from Denmark Recommendation of New-Active-Substances Presenter: Claus Loevschall, Denmark Presenter: Belen Sola, United Kingdom Poster Presentations Session 3: Lifecycle (Cost) Effectiveness Monday June 27, 13:40 – 13:50 Poster Stand 2, Mies Bouwman Foyer COVID & Patient/Public/Children PP19 Reimbursable Health Apps (DiGA) in Germany: Poster Stand 4, Mies Bouwman Foyer Which Factors Impact the BfArM’s Assessment and Directory Listing? – Updated Research PP41 COVID-19 Modelling to Support Decision Making in Brazil: A Scoping Review Presenter: Janika Drews, Germany Presenter: Michelle Rosa, Brazil PP20 Effectiveness and Safety of Autogenic Training as a Clinical Indication in Health Conditions PP42 Impact of the COVID-19 Pandemic in the Brazilian National Committee for Health Technology Presenter: Ana Toledo-Chávarri, Spain Incorporation (Conitec)’ Recommendation Process PP21 Efficacy and Safety of Aromatherapy: An Overview of Systematic Reviews Presenter: Marilia Cardoso, Brazil Presenter: Ana Toledo-Chávarri, Spain

POSTERS PP145 Improving Patient Expert Involvement in the PP40 Health Apps to Manage Depression: Can we Lifecycle of Health Technology Assessments to Build Separate the Grain from the Chaff? EvalDepApps Public Confidence in Decision Making Project Presenter: Heidi Livingstone, United States Presenter: Carrion Carme, Spain Lifecycle (Cost) Effectiveness Oncology Poster Stand 2, Mies Bouwman Foyer Poster Stand 1, Mies Bouwman Foyer PP35 Defecography (Evacuation Proctography) PP32 Assessment of Preferences for Treatment: A Discrete Choice Experiment Among Italian Patients Presenter: Andrey Avdeyev, Kazakhstan with Prostate Cancer PP36 Joint Replacement Under Computer Presenter: Eugenio Di Brino, Italy Navigation and Robotic Systems PP33 Molecular Markers for the Detection of Presenter: Andrey Avdeyev, Kazakhstan Clinically Significant Prostate Cancer PP37 A Systematic Review of Machine Learning and Presenter: Tasmania Del Pino-sedeño, Spain Statistical Models for Predicting Coronary Heart Disease in Diabetic Patients Poster Presentations Session 4: Monday June 27, 13:55 – 14:05 Presenter: Li Jiu, Netherlands COVID & Patient/Public/Children Lifecycle RWD & Quality of Care & Disinvestment Poster Stand 5, Mies Bouwman Foyer Poster Stand 3, Mies Bouwman Foyer PP56 The Use of Computed Tomography for Detecting COVID-19 Pneumonia: Rapid Evidence PP38 Does Changing the Specified Age of a Child Review Considered in EQ-5D-Y Based Valuation Studies Affect Health Preferences? Presenter: Samson Mideksa Legesse, Ethiopia Presenter: Mark Oppe, Netherlands PP43 Impact of the COVID-19 Pandemic on Scottish Medicine Consortium (SMC) Submission PP39 Evidence Generation for Reimbursement of Characteristics, Acceptance Rates, and Time to Digital Health Applications (DiGAs) in Germany Advice Presenter: Naomi Fujita-Rohwerder, Germany Presenter: Guy Berg, United Kingdom

POSTERS Lifecycle (Cost) Effectiveness Patient & Capacity Building Poster Stand 2, Mies Bouwman Foyer Poster Stand 3, Mies Bouwman Foyer PP50 A Systematic Review of Cost-Effectiveness PP53 Applying the Validate Approach to Frame the Analysis of Screening Programs for Chronic Kidney Assessment of Integrated Care Management in Disease Aortic Valve Stenosis Presenter: M. Rifqi Rokhman, Netherlands Presenter: Laura Sampietro, Spain PP51 Strengths and Limitations of Migraine PP54 Harmonising the Process of Developing Management Guidelines in the USA and Europe: A Clinical Practice Guidelines on Rare Diseases Across Targeted Literature Review Europe: Training and Capacity Building Presenter: Janet Ford, United States Presenter: Juan Antonio Blasco-Amaro, Spain PP52 Transcranial Magnetic Stimulation for the PP55 Clinical Practice Guidelines Development in Treatment of Cocaine Addiction: A Systematic Rare Diseases Using Health Technology Assessment: Review A Case Study of NKX2-1-Related Disorders Presenter: Ana Toledo-Chávarri, Spain Presenter: Juan Antonio Blasco-Amaro, Spain Oncology Poster Presentations Session 5: Monday June 27, 16:55 – 17:05 Poster Stand 1, Mies Bouwman Foyer Economic Evaluation PP47 Modelling Non-Small Cell Lung Cancer Treatment: Predicted and Observed Impact of Poster Stand 4, Mies Bouwman Foyer Immunotherapy in The Netherlands PP44 The Cost-of-Illness of the Management of Presenter: Zakile A Mfumbilwa, Netherlands Patients Affected by Thyroid Nodules in the Italian Healthcare Setting PP48 A Micro-Costing Study for Circulating Tumor DNA Testing in Oncology Presenter: Michele Basile, Italy Presenter: Astrid Kramer, Netherlands PP45 The Cost-of-Illness of Diabetic Macular Edema in Italy PP62 Recommendations on Methodologies to Obtain Comparator Efficacy in Health Economic Presenter: Michele Basile, Italy Assessments of Tumor-Agnostic Drugs Presenter: Reva Efe, Netherlands

POSTERS PP46 INEAS Guidelines for Pharmacoeconomic PP71 Lessons Learned During Analyses of Evaluation: Focus on HRQOL Recommendations Appropriate Hearing Care: Building Bridges Between Patient Organisations, Health Professionals and Presenter: Nabil Harzallah, Tunisia Insurance Companies Presenter: Mariska Stam, Netherlands Lifecycle (Cost) Effectiveness Pricing & MEA Poster Stand 2, Mies Bouwman Foyer Poster Stand 1, Mies Bouwman Foyer PP66 Safety, Effectiveness and Cost-Effectiveness of Scalp Cooling Devices for the Prevention of PP13 Development of Recommendations and Chemotherapy-Induced Alopecia Proposal for a Value-Based Managed Entry Agreement for Italian Setting Presenter: Tasmania Del Pino-Sedeño, Spain Presenter: Filippo Rumi, Italy PP67 Implantable Holter Monitor with Link -Online- PP14 Value-Based Pricing for Advanced Therapy Technology for Prolonged Cardiac Monitoring in Medicinal Products: Emerging Affordability Solutions Patients with Previous Stroke Presenter: Elisabete Gonçalves, Portugal Presenter: Juan Antonio Blasco-Amaro, Spain PP15 The National Pricing and Reimbursement Process in China, a 2021 Update PP68 DexcomG6® Device for Diabetes During Presenter: Xirong Song, United Kingdom Pregnancy Poster Presentations Session 6: Presenter: Ana Toledo-Chávarri, Spain Tuesday, June 28, Italy, 11:15 – 11:25 Patient & Capacity Building COVID & Patient/Public/Children Poster Stand 3, Mies Bouwman Foyer Poster Stand 4, Mies Bouwman Foyer PP69 Supporting Decision Making: A Health PP83 Economic Impact of Missed Vaccinations on Technology Assessment Training Proposal for the Italian NHS Decision Makers Presenter: Eugenio Di Brino, Italy Presenter: Maria-Jose Faraldo-Valles, Spain PP70 Enhancing HTA Processes in the Maltese System for Introducing New Medicines Presenter: Simone de Vries, Netherlands

POSTERS PP84 Change Management of Patient Associations PP88 Bayesian Joint Models for Cost-Effectiveness in Italy: From Emergency Response to Analyses Based on Clustered Participant Data, With Organizational Learning Implementation in Stan Presenter: Jonas Esser, Netherlands Presenter: Eugenio Di Brino, Italy PP140 Economic Evaluation of Several Vaccination PP85 The Cost-Effectiveness of the Anti-COVID Strategies Against Rotavirus in Spain Vaccination Campaign in the Italian Healthcare Presenter: Montserrat Carmona, Spain Setting Lifecycle (Cost) Effectiveness Presenter: Michele Basile, Italy Poster Stand 2, Mies Bouwman Foyer Early & General Lifecycle PP77 Safety, Effectiveness and Cost-effectiveness of Poster Stand 1, Mies Bouwman Foyer Telemedicine in Neurological Diseases Presenter: Ana Toledo-Chávarri, Spain PP74 Taking a Lifecycle Approach to Scottish Medicines Consortium Budget Impact Analysis PP78 Effectiveness and Safety of the FreeStyle Libre® Glucose Monitoring System for T1DM in Childhood Presenter: Corinne Booth, United Kingdom and Adolescence Presenter: Ana Toledo-Chávarri, Spain PP75 Incorporating Lifecycle Environmental Impact in the Economic Evaluation of Health Technologies: PP79 Use of Vagus Nerve Stimulation Therapy in Where Are We? Where Are We Going? Treatment-Resistant Depression Presenter: Andrey Avdeyev, Kazakhstan Presenter: Carmen Guirado-Fuentes, Spain Patient & Capacity Building PP76 Database on Evidence Based Telemedicine in a Hospital Setting Poster Stand 3, Mies Bouwman Foyer Presenter: Ida Wagner Svendsen, Denmark PP143 International Assessment of the Health Care System in Kazakhstan. A Performance Analysis Economic Evaluation Presenter: Lyazzat Kosherbayeva, Kazakhstan Poster Stand 5, Mies Bouwman Foyer PP86 Gender-Neutral Human Papilloma Virus Vaccination: More Than Cost-Effectiveness Presenter: Carmen Guirado-Fuentes, Spain

POSTERS PP81 Barriers to Implementation of Health PP99 Innovating for Decreasing Mortality and Technology Assessment Resource use in Surgical Inpatient: The Zero Project Presenter: Lyazzat Kosherbayeva, Kazakhstan Presenter: Carla Fernandez Barcelo, Spain PP82 First Educational Trainings According to PP100 Improving the Assessment of Effectiveness New Health Technology Assessment Guideline For for Digital Applications using B Statistic: Using Medicines in Ukraine WtsWrng as Case-Study Presenter: Oresta Piniazhko, Ukraine Presenter: Carla Fernandez Barcelo, Spain Poster Presentations Session 7: Lifecycle (Cost) Effectiveness Tuesday June 28, 13:10 – 13:20 Poster Stand 2, Mies Bouwman Foyer Early & General Lifecycle PP101 Development Process of the Economic Poster Stand 1, Mies Bouwman Foyer Guidelines in Tunisia Presenter: Nabil Harzallah, Tunisia PP02 Is Glycated Hemoglobin a Valid Surrogate to Evaluate the Effectiveness of Drugs in Diabetes PP102 Selecting the Sequence of Diagnostic Tests Mellitus Studies? for Leprosy in Brazil Presenter: Paola Rivera, Peru Presenter: Bruno Barros, Brazil PP03 Early Assessment of Video Consultations in Patient & Capacity Building Rehabilitation After Hand Injury Presenter: Linn Nathalie Stome, Norway Poster Stand 3, Mies Bouwman Foyer HTA Findings PP95 Health Professionals’ Participation on Health Technology Assessment (HTA) Public Consultation: Poster Stand 4, Mies Bouwman Foyer A Distribution Analysis of Brazilian HTA in 2021 Presenter: Denis Satoshi Komoda, Brazil PP98 Occupational Therapy for Adult Persons With Cognitive Impairments: A Systematic Overview on PP96 Joint Clinical Assessments – Implementation Clinical Efficacy and Lessons for the Next Stage of EU HTA Presenter: Petra Schnell-Inderst, Austria Presenter: Dima Samaha, United Kingdom

POSTERS PP97 Recommendations for Generating South PP118 Cyclic Mental Health Technology Assessment; African Health-Related Quality of Life Data for Cost- Priority Setting and Involving Stakeholders; A Case Utility Analyses Report from the Netherlands Presenter: Sophia Emmarenzia Marsh, United Presenter: Koen Böcker, Netherlands Kingdom PP119 Results and Lessons Learned from the Cyclic Poster Presentations Session 8: Appropriate Care Program from National Health Tuesday June 28, 13:25 – 13:35 Care Institute of the Netherlands HTA Methods Presenter: Hedy Maagdenberg, Netherlands Poster Stand 4, Mies Bouwman Foyer Oncology PP114 Analysis of the Influence of Implicit Factors Poster Stand 1, Mies Bouwman Foyer on HTA Deliberative Process: Results of a Survey in 5 European Countries PP120 Fluorescent in Situ Hybridization (FISH) vs Conventional Cytogenetic (CC) for Detecting High- Presenter: Clara Monleon, Switzerland Risk Genetic Mutations in Multiple Myeloma PP115 Analysis of Previous Joint Clinical Presenter: Denis Satoshi Komoda, Brazil Assessment and Potential Transferability to Four European Countries: Case Study and Conceptual PP121 High Dose Chemotherapy or Standard of Approach Care for BRCA1-like Stage III Breast Cancer Patients: A Discrete Choice Experiment Presenter: Jeanne Kern, Switzerland Presenter: Joost Verbeek, Netherlands Lifecycle RWD & Quality of Care & Disinvestment PP122 MR-guided HIFU for Non-Surgical Treatment of Prostate Cancer, Uterine Fibroids, Adenomyosis Poster Stand 5, Mies Bouwman Foyer and Pain in Bone Metastases PP117 Larger Impact of an Appropriate Care Presenter: Andrey Avdeyev, Kazakhstan Program by Involving Health Care Professionals; A Case Report on Cervical Pre-malignancy Pricing & MEA Presenter: Thom de Bruijin, Netherlands Poster Stand 3, Mies Bouwman Foyer PP111 Reimbursement and Payment Models: A Survey of Stakeholders’ Current Experiences and Future Outlook Within the Dutch Policy Setting Presenter: Marcelien Callenbach, Netherlands

POSTERS PP112 Reimbursement Decisions for Medical PP133 Cost Spent on Early Discontinuation of Services in Austria: An Analysis of Influencing Factors Treatment with Anti-cancer Medication in the for the Hospital Individual Services Catalogue Netherlands Presenter: Gregor Goetz, Austria Presenter: Rick Vreman, Netherlands PP113 Reimbursement of Oncology Therapies with PP134 Health Technology Assessment Life Cycle Limited Clinical Evidence in the Netherlands Approach in Asthma Care Presenter: David Smalbrugge, Netherlands Presenter: Geert van Kemenade, Netherlands Poster Presentations Session 9: Other Tuesday June 28, 13:40 – 13:50 Poster Stand 1, Mies Bouwman Foyer Lifecycle (cost)effectiveness PP138 Heuristics and the Decision to Share Health Poster Stand 2, Mies Bouwman Foyer Data: A Qualitative Study PP123 Fair Drug Pricing: Review of Literature and Presenter: Anna Hermansen, Canada Models PP103 Early HTA of integrated care to increase Presenter: Olena Wagner, Ukraine employment for persons with substance use disorder PP125 Economic Evaluation of Molecular Diagnostics –A Review and Future Directions Presenter: Linn Nathalie Stome, Norway Presenter: Janet Bouttell, United Kingdom PP34 NGS for Informing Lung Cancer Therapy in Europe – Hospital Impact with a Lifecycle PP108 Multidimensional Analysis of Peristeen Plus Perspective Medical Device Presenter: Rhodri Saunders, Germany Presenter: Filippo Rumi, Italy Patient & Capacity Building Lifecycle RWD & Quality of Care & Disinvestment Poster Stand 3, Mies Bouwman Foyer Poster Stand 5, Mies Bouwman Foyer PP126 Direct Patient Involvement in HTA in Canada and Brazil: The Patients Perspectives PP132 Disinvestment Initiatives in Healthcare: A Scoping Review Of Systematic Reviews Presenter: Aline Silveira Silva, Canada Presenter: Hanin Kamaruzaman, United Kingdom

POSTERS PP127 Impact of Brazilian Patient Testimonials Poster Presentations Session 10: on Medical Devices and Public Confidence in the Tuesday June 28, 16:35 – 16:45 Healthcare Decision-Making Economic Evaluation Presenter: Aline Silveira Silva, Canada Poster Stand 4, Mies Bouwman Foyer PP128 Development and Piloting of an Online Training Course on Health Technology Assessment PP146 The Use of Indirect Comparisons for for Patients Reimbursement Decision Making in the Netherlands and England Presenter: Yolanda Triñanes, Spain Presenter: Rachel Kalf, Netherlands Pricing & MEA PP147 Conditional Reimbursement of Medicinal Poster Stand 4, Mies Bouwman Foyer Products, A Procedure for Orphan Drugs, Conditionals and Exceptionals PP129 Usefulness, Acceptability and Satisfaction of a Decision-Making Tool for Clinical Meso- Presenter: Floor Van Heesch, Netherlands Management in Type 2 Diabetes Mellitus PP148 The Impact of Health Technology Wales Presenter: Ana Toledo-Chávarri, Spain Guidance for Autologous Haematopoietic Stem Cell Transplantation: Two Years Post-Publication PP130 Fair Pricing Models for Innovative Orphan Medicines: A Case Study Presenter: Lauren Elston, United Kingdom Presenter: Noa Rosenberg, Netherlands Patient & Capacity Building PP131 European Market Access Landscape Analysis Poster Stand 3, Mies Bouwman Foyer of Reimbursement Drivers in Pompe Disease: Results from 26 Payer Interviews PP149 A Multidimensional and Multistakeholder Approach: Assessing ELSI+ for Telemedicine in Presenter: Alasdair Macculloch, United Kingdom Neurological Diseases Presenter: Ana Toledo-Chávarri, Spain PP150 The Role of Expert Consensus in UK Guidance: Patient Selection for Hydrogel Spacer Use During Prostate Cancer Radiotherapy Presenter: Emily Woodward, Switzerland PP151 VALIDATE Methodology on a Medication Related Clinical Decision Support System: Holistic Assessment for Optimal Technology Adoption Presenter: Carla Fernandez Barcelo, Spain

POSTERS Poster Displays Expo Hall and Virtual Meeting Platform PD43 Estimating Societal Costs Associated with Vision Loss and Delayed Cataract Surgery: The COVID & Patient/Public/Children Potential Impact of the COVID-19 Pandemic PD33 Development and Validation of a Machine PD44 Realistic Review: Theoretical Model Learning-Based Prediction Model for COVID-19 for Monitoring and Evaluation (M&E) of HTA Diagnosis Using Patients’ Metabolomic Profile Data Management PD34 Neuron-specific Biomarkers Associated PD45 Paying for Digital Health: What Evidence is with Neurological Manifestations in COVID-19: An Needed? Evidence Mapping Systematic Review PD46 Multi-criteria Decision Analysis in Healthcare: PD35 Mortality and Risk Factors Associated with Scientometric and Bibliometric Analysis Dialysis Patients with COVID-19 in a Brazilian Supplementary Health Service PD48 Does Unmet Need Influence the Scottish Medicines Consortium Health Technology PD36 Outcomes of Centenaries Hospitalized due to Assessment Decisions for Rare Disease Conditions? COVID-19 in a Private Healthcare System PD49 Burden and Cost Oo Anterior Cruciate PD37 High-Dose Vitamin D for the Treatment of Ligament Reconstruction Aad Reimbursement of its Covid-19 Treatment in Indonesia: An Observational Study PD38 Telehealth Use to Fight the Covid-19 PD50 Value of Healthcare Journey for Patients with Pandemic in a Brazilian Private Healthcare System Rare Diseases in Brazilian Public Healthcare System: Methods and Preliminary Results PD39 Strategies to Assist People with Disabilities During Health Emergencies, Concerning the PD51 Patient Perspective: A Preliminary Analysis of COVID-19 – Systematic Review the First Year of the Patient Involvement in Conitec´s Meetings PD40 Antigen Diagnostic Tests with Self-Collection of Biological Material for the Diagnosis of COVID-19 PD52 The Role of Public Consultations in Conitec’s Recommendations Between 2012 And 2020: An PD41 Role of Artificial Intelligence in Improving Introductory Analysis Access to COVID-19 Diagnosis During Pandemic PD53 Improving Patient Involvement in the National Institute for Health and Care Excellence’s Appeals PD42 Diagnosis of Chronic Diseases During the Process COVID-19 Pandemic Through Telemedicine

POSTERS PD54 Burden of Disease and Risk Factors Among Late Lifecyle RWD & Quality of Care Children Under 5 years in China from 1990 to 2019 & Disinvestment PD55 Evidence-Based Practices to Support Well- PD20 Real-World Evidence to Support Single Arm Being and School Success of Children and Youth in Trials of Oncology Interventions: Necessity or ‘NICE’ Out-of-Home Care to Have? PD56 Conceptual Issues in the Valuation of Health PD21 Data Sources and Real-World Data on Medical States in Children Devices in the Brazilian Scenario Early & General Lifecycle PD22 Exploratory Analysis of a Brazilian Real-World Open Database Applied to Prostate Cancer PD14 A New Equitable Biomedical Research and Development Model: Preliminary Findings From a PD23 Assessing the Suitability of Real-World Data Pilot Study Applying VALIDATE Value Methods for Answering Decision Problems – NICE’s Data Suitability Assessment Tool PD15 Horizon Scanning to Nominate Subsidy Evaluation Topics for Medical Technologies: Early PD24 Robust Real-World Evidence Generation in Experience from Singapore Comparative Effectiveness Studies – NICE’s Methods Framework PD16 Reassessment and Selection Strategy of Dipeptidyl Peptidase-4 Inhibitors for Ministry Of PD25 Use of Real-World Evidence in the Health Malaysia Medicine Formulary Reimbursement Assessment of Medical Devices PD17 Automating the Impact Reporting of NICE PD68 Disinvestment Initiatives in Healthcare: A Guidance Scoping Review of Systematic Reviews PD18 Early Value Assessments of Technologies in Lifecycle (Cost) Effectiveness the NICE Diagnostics Assessment Programme PD01 Using ELISA Tests for Monitoring Response to PD19 Machine Learning Modelling for Clinical Trial Anti-TNFs in Rheumatoid Arthritis: Findings From a Design Using the NIHR Innovation Observatory’s NICE Health Technology Assessment ScanMedicine Database PD02 A Literature Review of Treatment Schemes and PD64 Developing a Re-assessment Process for Effects of Beta-thalassemia in China Non-medicine Health Technologies in Wales PD03 Sedimentation of Health Technology Assessment In Hospitals: A Scoping Review PD04 Supporting the Social Integration of Persons with Brain Injury Using Psychoactive Substances: A Health Technology and Intervention Assessment

POSTERS PD05 Novel Non-Thermal Ablation Technology for Oncology the Treatment of Atrial Fibrillation PD26 Overscreening for Older Women in Cervical PD07 Cost-effectiveness pf Non-vitamin K and Breast Cancer Screening in Japan Antagonist Oral Anticoagulants in Chinese Patients With Atrial Fibrillation PD27 Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with PD08 A Systematic Review of Reporting Quality of Traditional Chinese Medicine in China Economic Evaluations in TCM in NRDL of China Based on CHEERS PD28 Cost-Effectiveness of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres PD09 Comparing Long-Term Costs Associated for Unresectable Hepatocellular Carcinoma in Brazil with Intraocular Lens Selection and Nd:YAG Laser Capsulotomy in the UK: A Cost-Consequence PD29 Systematic Review with Meta-analysis of Analysis Pharmacokinetic Parameters of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia PD10 Quality of Economic Evaluation of Coronary Stents Based on CHEERS: A Scoping Review PD30 The Radioactive Seed Localization and Radio- Guided Occult Lesion Localization for Non-Palpable PD11 Cost-Effectiveness of Continuous Glucose Breast Cancer Surgery: A Meta-Analysis Monitoring for Paediatric Patients with Type 1 Diabetes Compared with Self-Monitoring of Blood PD31 A Pragmatic and Expedited Evaluation of Glucose Companion Diagnostics for Guiding Cancer Drug Use PD12 Quality Assessment of Health Economic Evaluation on Screening Programs from China PD32 Cost-Utility of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for PD13 Methodologies In Economic Evaluations Of Chemotherapy-Refractory Metastatic Colorectal Biomarkers – A Systematic Review Cancer in Brazil PD65 Efficacy and Safety of High Intensity Focused Patients & Capacity Building Ultrasound in Parkinson’s Disease PD57 Managing Innovation: A Qualitative Analysis PD66 An External Combined Occipital and of Different Structures in Health and Social Services Trigeminal Neurostimulation Device for Migraine Institutions Treatment PD58 Implementation and Assessment of a Lung PD67 The Importance of Flexible PPI Approaches: Cancer Screening Pilot Project in Québec Through Case Study on Flash Glucose Monitoring Multi-Stakeholder Collaboration PD66 An External Combined Occipital and Trigeminal Neurostimulation Device for Migraine Treatment

POSTERS PD59 Collaborative Strategies Between Regulatory and Health Technology Assessment Bodies: Results of Teaching and Learning Initiatives PD60 What are the Opportunities and Challenges to Implement Value Based Healthcare (VHBC) Pilots in Brazilian Private Healthcare System? Pricing & MEA PD61 What are the Drivers to Transitioning from FFS to Value-Based Payments Models in the Brazilian Private Healthcare System? PD62 Supporting Appropriate Medicines Use Through the Lifecycle: Bringing Standardised Patient Data Into Clinical Practice with the H2O Project

HTAI AND ASSOCIATED MEETINGS HTAi and Associated Meetings 97

HTAI AND ASSOCIATED MEETINGS HTAi Policy Forum Meetings and Sessions HTAi and Associated Meetings Saturday, June 25, 2022 Sunday, June 26, 2022 HTAi Board of Directors Meeting (Invitation Only) Global Policy Forum: The Business and Topic 08:30 – 16:30, Room 116 (1st Floor) Scoping Meeting (Invitation Only) 09:00 – 12:00, Room 417 (4th Floor) Sunday, June 26, 2022 Monday, June 27, 2022 Euroscan Meeting (Invitation Only) 13:00 – 15:30, Room 417 (4th Floor) HTA 2025 and Beyond: Lifecycle Approaches to Promote Engagement and Efficiency in Health HTAi Scientific Development and Capacity Building Technology Assessment (2022 Global Policy (SDCB) Committee Meeting (Invitation Only) Forum) 16:30 – 17:30, Room 417 (4th Floor) 14:20 – 15:35, Beatrix Theatre (Ground Floor) Monday, June 27, 2022 Deliberative Processes for Informed Decision Making by Health Technology Assessment Annual General Meeting (AGM) (2021 Latin America Policy Forum) 19:00 – 20:00, Beatrix Theatre (Ground Floor) 17:15 – 18:30, Beatrix Theatre (Ground Floor) Tuesday, June 28, 2022 Tuesday, June 28, 2022 IJTAHC Editorial Board Meeting (Invitation Only) HTA in Asia Post-COVID-19 (2021 Asia Policy 12:55 – 13:55, Room 110 (1st Floor) Forum) 16:55 – 18:10, Beatrix Theatre (Ground Floor)

HTAI AND ASSOCIATED MEETINGS HTAi Interest Group Meetings Monday, June 27, 2022 Tuesday, June 28, 2022 HTAi Interest Group Meeting: Hospital Based HTA HTAi Interest Group Meeting: Ethics in HTA 12:30 – 13:30, Room 417 (4th Floor) 12:55 – 13:55, Room 315 (3rd Floor) HTAi Interest Group Meeting: Real World Evidence HTAi Interest Group Meeting: Patient and Citizen & Artificial Intelligence Involvement 12:30 – 13:30, Room 215 (2nd Floor) 12:55 – 13:55, Room 215 (2nd Floor) HTAi Interest Group Meeting: Medical Devices HTAi Interest Group Meeting: Public Health 12:30 – 13:30, Room 315 (3rd Floor) 12:55 – 13:55, Room 417 (4th Floor) HTAi Interest Group Meeting: Disinvestment & Early Awareness 18:15 – 19:15, Room 417 (4th Floor) HTAi Interest Group Meeting: HTA in Developing Countries 18:15 – 19:15, Room 215 (2nd Floor) HTAi Interest Group Meeting: Information Retrieval 18:15 – 19:15, Room 315 (3rd Floor)

Novartis sponsored symposium at the Health Technology Assessment international 2022 Annual Meeting Facilitating RWE Use in HTA: Creating a Taxonomy for Problem Solving and Data Legitimization Tuesday 28th June 2022, 12.55 – 13.55 (CEST) HTAi Annual Meeting – Utrecht, Netherlands Faculty Prof. Ron Akehurst, United Kingdom Prof. Akehurst is Executive Chair of HEOR at Lumanity and is a member of the NICE Highly Specialized Technologies Committee and Rare Diseases Advisory Group at NHS England. He is Professor Emeritus in Health Economics (University of Sheffield) and visiting Professor at Eotvos Laurent and Corvinus Universities (Budapest). He was founding Dean of ScHARR (University of Sheffield), and worked for 40 years as an academic. Ron was a founding member of the NICE Appraisal Committee and served on the NICE Topic Selection Committee, Public Health Interventions Advisory Committee and Diagnostics Advisory Committee. Dr. Oriol Solá-Morales, Spain Dr. Solá-Morales has served as Director of a regional HTA authority in Spain, is a founding member of EUnetHTA and has been advisor to three Catalan Ministers of Health. He founded HITT, an Early Market Access consultancy and has worked with major pharma as an interim MA Director, a consultant and as an advisor. He has designed and implemented medical and MA strategies for several start-ups, as well as for Top 10 pharma companies. Oriol is also an assistant professor in several Masters’ degrees, nationally and internationally. Dr. Linda Murphy, Ireland Dr. Murphy is a Senior Director of HEOR Insight at Lumanity providing HEOR support for health technologies, primarily for strategic planning for HTA submissions. Linda has worked in the MedTech industry in varying R&D and Quality Assurance roles. She has a PhD in Bioengineering and has lectured on the Bioengineering Masters course in Trinity College Dublin. She also worked as an Assessment Manager in the Health Information and Quality Authority (HIQA) in Ireland supporting HTAs to inform national policy decisions regarding medical devices, diagnostics, surgical procedures and screening programmes. Dr. Jorge Mestre-Ferrandiz, Spain Dr. Mestre-Ferrandiz is an independent economics researcher and consultant since 2017, based in Madrid, Spain. He is Profesor Asociado at University Carlos III, Madrid, and Co-Editor of the Blog Economia y Salud. Jorge spent 15 years at The Office of Health Economics with various positions, finishing as Director of Consulting. He has 20 years’ experience consulting to the pharmaceutical industry, public organizations, and related non-profit and non-governmental organizations. Jorge has a PhD in Economic Analysis from the University Autonoma of Barcelona and has published over 60 papers on health economics. To discuss the extent of this work and its value to HTA practitioners and decision makers in supporting the use of RWE in HTA. The session will focus on gathering feedback on the value of the taxonomy in its current format and how it might be improved upon. A further important strand of discussion will be on the gathering of feedback on a data governance checklist. 12.55 – 13.00 Overview of challenges of RWE use in HTA decision making – Jorge Mestre-Ferrandiz 13.00 – 13.05 Introduction to EUreccA 2025 RWE project – Ron Akehurst 13.05 – 13.20 Outputs of project: Overview of Data Governance Checklist – Oriol Solà-Morales 13.20 – 13.30 Outputs of project: Overview of Taxonomy - Ron Akehurst 13.30 – 13.40 Worked examples from Taxonomy – Linda Murphy 13.40 – 13.55 Q&A and Discussion - Jorge Mestre-Ferrandiz This satellite symposium is organized and funded by Novartis Pharma AG ©Novartis Pharma AG, 2022, CH-4002 Basel, Switzerland June 2022

SYMPOSIA Symposia 101

SYMPOSIA Symposia Monday, June 27, 2022 You Better Believe It: Methodologies to Address Concerns in Using Real-World Evidence for Measures of Treatment Effectiveness F. Hoffman-La Roche Ltd 10:45 – 12:00, Room Beatrix Theatre Moderator: Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), F. Hoffman-La Roche Ltd, Switzerland Panelists: Robert Cook, Senior Principal, Health Policy & Insights, Economist Intelligence Unit, London, United Kingdom Grace Hsu, Associate Director & Research Principal, Cytel, Canada Miguel Hernán, Professor of Biostatistics and Epidemiology, Harvard T.H. Chan School of Public Health, USA Seamus Kent, Senior Adviser in Data & Analytics, National Institute for Health and Care Excellence, United Kingdom Medicines development for rare-disease is increasingly reliant on single-arm trials which pose challenges for health technology assessment (HTA). We provide an overview of real-world evidence used in treatment effectiveness decision-making for HTA, and to understand concerns of bias regarding internal and external validity. Methodological approaches to address these concerns and results from studies applying these methods in oncology will be discussed.

SYMPOSIA Making Gene and Cell Therapies RealityfFor Patients: How HTA And Novel Payment Solutions Play a Central Role F. Hoffman-La Roche Ltd 13:15 – 14:15, Room 114 (First Floor) Moderator: Clifford Goodman, Sr Vice President, The Lewin Group, United States Panelists: Karen Facey, Evidence Based Health Policy Consultant and Visiting Senior Research Fellow, University of Edinburgh, Scotland Jessica Bean, Chair at Patient Voice Initiative, Patient Voice Initiative, Australia Samir Megatelli, Franchise Head Neuromuscular Diseases, Enabling Rare & Gene Therapy Network, Global Strategy NS&RD, F. Hoffmann-La Roche Ltd, Switzerland Bringing together diverse stakeholder perspectives, this session will explore the critical HTA role in achieving the best patient outcomes, benefiting from cell and gene therapies. This will address HTA adaptations of patient-centered priorities, challenges and solutions for these therapies, and how HTAs can ensure that the key stakeholders are engaged in ways that benefit patients, clinicians, policymakers, and innovation. What does ‘Value’ mean in Cancer Policy & Practice? Interventions for Improved Patient Outcomes across Geographies Merck & Co., Inc. 13:15 – 14:15, Room 117 (First Floor) Moderator: Dr. Bettina Ryll, Founder, Melanoma Patient Network Europe Panelists: Dr. Marianna de Camargo Cancela, Section Chief, National Institute of Cancer – Brazilian Ministry of Health (Grantee, Brazil) Dr. Salvador Acevedo-Gómez, Medical Researcher, Tómatelo a Pecho A.C. (Grantee, Mexico) Dr. Patrick Jeurissen, Professor, Radboud University Medical School, London School of Economics and Political Science; Scientific Advisor, Ministry of Health, Welfare, and Sport (Policymaker) Prof. David Taylor, Professor, School of Pharmacy, University College London (Grantee, U.K.) Cancer is one of the leading causes of death worldwide and will continue to challenge diverse healthcare systems. Experts of the MSD Oncology Policy Grants Program will explore insights from their research in Brazil, Mexico, and the United Kingdom and discuss interventions they consider the most impactful to improve cancer outcomes. Together with experts from advocacy and government, they will debate the dimensions of ‘value’: How can we measure it? How can we use it for evidence-based policy and practice?

SYMPOSIA Tuesday, June 28, 2022 Facilitating RWE Use In HTA: Creating a Taxonomy for Problem Solving and Data Legitimization Novartis Ireland Ltd. 12:55 – 13:55, Room 114 (First Floor) Moderator: Jorge Mestre-Ferrandiz, Independent Economics Consultant, Spain Panelists: Ronald L. Akehurst, Chairman, BresMed Health Solutions, United Kingdom Oriol Solà-Morales, President Fundació HiTT & CEO at HITT, Spain Linda A. Murphy, Senior Director, Lumanity, Ireland We examined how RWE is used in HTA decision making as part of a wide collaboration to improve the usability of RWE. We recommend practical solutions to support this. We used a range of methods (literature reviews, expert elicitation, country case studies and RWE use case studies) to create a taxonomy (uses/ sources) and a data governance framework. Capacity-Enhancing Innovations as Enablers for Resilient Healthcare Systems Edwards Lifesciences 15:10-16:25, Room - Beatrix Theatre (Ground Floor) Moderator: Mr. Andrea Rappagliosi, Senior Vice President, Public Affairs EMEA-Canada-LatAm, Edwards Lifesciences Panelists: Dr. Sean Tunis, Center for Medical Technology Policy (CMTP) and Former President of HTAi Board of Directors Dr. Wija Oortwijn, Current President of HTAi Board of Directors and member of the HTAi Global Poliy Forum Dr. Laura Sampietro-Colom, Deputy Director of Innovation and Head of the Health Technology Assessment (HTA) Unit at the Hospital Clinic of Barcelona; Former President of HTAi Board of Directors and former Chair of HTAi Global Policy Forum and LatAm Policy Forum Dr. Seth Clancy, Senior Vice President, Global Health Economics and Reimbursement - THV, Global Public Affairs, Edwards Lifesciences Recent COVID-19 pandemic highlighted the need for more robust and agile healthcare systems. This shift, requires the adaptation of the HTA processes to maintain access to innovative technologies for all patients while securing the highest standard of care for urgent cases like COVID-19 patients. Capacity- enhancing innovations can enable access to needed care while reducing burdens on healthcare providers and hospitals.

SPONSORS /EXHIBITORS Sponsors / Exhibitors 105

SPONSORS /EXHIBITORS Platinum Sponsors Edward Lifesciences Health Technology Wales Website: https://www.edwards.com Website: https://healthtechnology.wales Edwards Lifesciences is the global leader of patient- Health Technology Wales is a national body working to focused innovations for structural heart disease and improve the quality of care in Wales. critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives It works in collaboration with partners across the health, through partnerships with clinicians and stakeholders social care and technology sectors to assess non- across the global healthcare landscape. For more medicine health and care technologies for use in health information, visit Edwards.com and follow us on and social care settings in Wales. Facebook, Instagram, LinkedIn, Twitter and YouTube. HTW’s work informs commissioning by NHS Wales and care providers and supports decision makers to make evidence informed decisions on both technology investments and disinvestments. It is funded by Welsh Government and hosted by the Velindre University NHS Trust but is independent of both. HTW was established by ministerial recommendation in 2017 following the National Assembly for Wales’ inquiry into Access to Medical Technologies in Wales. F. Hoffman-La Roche Ltd Website: https://www.roche.com Roche focuses on finding new medicines and diagnostics and establishing data-based insights that evolve the practice of medicine and help patients live longer, better lives.

SPONSORS /EXHIBITORS HEALTH ECONOMICS and ZonMw HEALTH TECHNOLOGY ASSESSMENT Website: https://www.zonmw.nl/ HEHTA_University of Glasgow ZonMw stimulates health research and care innovation throughout the entire knowledge chain from Website: https://www.gla.ac.uk/researchinstitutes/ fundamental research to implementation. Through healthwellbeing/research/hehta/ various subsidy programmes we promote and fund development and practical application in the area of Health Economics and Health Technology Assessment prevention improvement, health and care. ZonMw (HEHTA) is a research group at the University of Glasgow supports HTA with a HTA Methodology program. dedicated to research that impacts clinical practice, population health and health policies, including economic evaluation alongside trials, decision analytic modelling, evidence synthesis, population health economics, precision medicine, global HTA, medical statistics and qualitative evaluations. Radboudumc Website: https://www.radboudumc.nl/en/patient-care Radboudumc is a university medical center for patient care, research and education, located in Nijmegen, the Netherlands. We want to play a leading role in the development of innovative, sustainable and affordable healthcare. Our mission statement is: ‘to have a significant impact on healthcare’. We achieve that by providing person-oriented care, distinctive quality, efficiency and sustainable networks. Nearly 10,000 employees and 3,500 students are working on the future of healthcare and medical sciences. We participate in the Guild of European Research-Intensive Universities, comprising nineteen of Europe’s most distinguished universities in fourteen countries. The Guild is committed to the pursuit of excellence science as the foundation of public life, and the creation of new knowledge for the benefit of society, culture, and economic growth.

SPONSORS /EXHIBITORS Diamond Sponsors F. Hoffman-La Roche Ltd National Health Care Institute Netherlands Website: https://www.roche.com Website: https://english.zorginstituutnederland.nl Roche is the leader in personalised healthcare. Our Mission – Taking care of good health care We provide breakthrough medicines and diagnostic tests Every person residing or working in the Netherlands using expertise in science, technology and data so that is entitled to good care services from the basic health people can live better lives. insurance package. The National Health Care Institute is a government organization whose main task is to put Our company has a 125-year history of advancing the together the basic health insurance package. Our goal is field of medicine and bringing novel treatments and that everyone in the Netherlands - rich and poor, young diagnostics to patients. The patient is and will remain at and old, healthy and sick - can receive good care. Now the core of what we do, the reason we come to work and in the future. every day. Merck & Co., Inc Novartis Pharma AG Website: https://www.msd.com Website: https://www.novartis.com/ At MSD, known as Merck & Co., Inc., Rahway, NJ, USA Novartis is reimagining medicine to improve and extend in the United States and Canada, we are unified around people’s lives. As a leading global medicines company, our purpose: We use the power of leading-edge science we use innovative science and digital technologies to save and improve lives around the world. For more to create transformative treatments in areas of great than a century, we’ve been at the forefront of research, medical need. In our quest to find new medicines, we bringing forward medicines, vaccines and innovative consistently rank among the world’s top companies health solutions for the world’s most challenging investing in research and development. Novartis diseases. products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments.

SPONSORS /EXHIBITORS Gold Sponsors Institute of Health Economics Medtronics Website:https://www.ihe.ca Website: https://www,medtronic.com The Institute of Health Economics is an independent, As a global leader in medical technology, services and not-for-profit organisation with key competencies in solutions, Medtronic improves the lives and health of health economics, health technology assessment, and millions of people each year. We use our deep clinical, knowledge transfer. Our mission is to provide relevant, therapeutic and economic expertise to address the timely and impactful evidence that supports informed complex challenges faced by healthcare systems today. health system policy and investment decisions, working Let’s take healthcare Further, Together. Learn more at with public and private partners. Medtronic.com. Intuitive Sanofi Website: https://www.intuitive.com Website: https://www.sanofi.com Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, We are an innovative global healthcare company, driven California, is a global technology leader in minimally by one purpose: we chase the miracles of science to invasive care and a pioneer of robotic-assisted surgery. improve people’s lives. Our team, across some 100 As part of our mission, we believe that minimally countries, is dedicated to transforming the practice of invasive care is life-enhancing care. Through ingenuity medicine by working to turn the impossible into the and intelligent technology, we expand the potential of possible. We provide potentially life-changing treatment physicians to heal without constraints. options and life-saving vaccine protection to millions of people globally, while putting sustainability and social Intuitive brings more than two decades of leadership in responsibility at the center of our ambitions. robotic-assisted surgical technology and solutions to its offerings and develops, manufactures, and markets the da Vinci® surgical system and the Ion® robotic bronchoscopy system. Learn more at Intuitive.com.

SPONSORS /EXHIBITORS Exhibitors Cochrane INAHTA Website: https://training.cochrane.org/ Website: https://www.inahta.org Cochrane is delighted to announce the availability of The international Network of Agencies for Health RevMan Web, its popular, web-based systematic-review Technology Assessment (INAHTA) is a network of 50 production software, to the wider community beyond publicly funded HTA agencies that support health Cochrane – to support evidence synthesis development. system decision making that affects over 1 billion people Cochrane anticipates considerable interest in use in 30 countries around the globe. INAHTA brings HTA of RevMan Web from those in Guideline and Health agencies together to share knowledge and tools to Technology Assessment organisations. strengthen their role as essential contributors to health outcomes and health system sustainability. ConnectHEOR Synergus RWE Website: https://www.connectheor.com Website: https://www.synergusrwe.com/ EuroScan

SPONSORS /EXHIBITORS 2RIME0PPOA2CR1TT This report is a summary of our work in 2021 and what we have achieved as a national health technology assessment (HTA) organisation. Thank you to everybody who collaborated with us in 2021 and enabled us to continue supporting the health and care sectors in Wales. 88 9 6 49 Topics proposed to Health Evidence appraisals Pieces of national guidance Topic exploration Technology Wales published published reports produced 188,680 individuals will be “HTW’s delivery has been really impressive.“ Types of recommendation made impacted in Wales if HTW HTW has remained absolutely focussed “ in HTW guidance in 2021 guidance published since on its core purpose, delivering a rapid streamlined approach to the identification, 1177%% 2017 is implemented. appraisal and adoption of health and care 883%3% New economic analysis to technologies in Wales. This and the open assess cost effectiveness in call methodology has ensured really strong Routine adoption Insufficient evidence to adopt Wales was undertaken for 5 stakeholder relationships, and agile delivery, pieces of national guidance particularly in response to the pandemic, in 2021 where HTW made an important contribution. Ifan Evans, former Director - Technology, Digital & Transformation, Welsh Government Better Health | Evidence Driven Advisory committee In 2021 we established a collaborative meetings hosted: partnership with Social Care Wales and published our first 5 Appraisal panels piece of social care guidance on START - a support programme for carers of people with dementia. 10 Assessment groups “Over the last year we’ve Throughout 2021 we worked with 3 Executive groups global partners to create position 3 Industry user groups continued to work closely with the statements for the International 4 Patient and public team at Health Technology Wales. It’s been – and continues to be – a true collaboration, Network of Agencies for Health involvement (PPI) and we’re looking forward to our future work Technology Assessment (INAHTA). standing groups to promote and embed the practice of health HTW was also awarded the Website technology assessment in social care in David Hailey Award for Best Impact Wales. Story at the INAHTA 2021 Congress. 53,118 Webpage views 15,673 Unique visitors Lisa Trigg, Assistant Director of Research Data and Intelligence, Social Care Wales In March 2021 HTW was appointed a Collaborating Partner of the Wales COVID-19 Evidence Centre (WCEC) WCEC COLLABORATING PARTNERS www.healthtechnology.wales Health Technology Wales @HealthTechWales Annual Report 2021 [email protected]